Cargando…
Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile and the target Phase I...
Autores principales: | Mangel, Allen W, Hicks, Gareth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278196/ https://www.ncbi.nlm.nih.gov/pubmed/22346361 http://dx.doi.org/10.2147/CEG.S23274 |
Ejemplares similares
-
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016) -
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017) -
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016) -
Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012) -
Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)